Established in 2000, IntegraGen (member of the OncoDNA Group) specializes in the genomic analysis of all nucleic acids, with a particular focus on cancer and rare genetic diseases. Backed by highly experienced and qualified teams, IntegraGen is a leading player in DNA and RNA sequencing services as well as genomic data interpretation software development. The company runs one of the largest NGS labs in France and for services for most research institutes of excellence as well as private and public institutions and companies across Europe.

IntegraGen laboratory was granted the CAP (college of American Pathologists) accreditation in December 2023 and became CLIA certified in January 2024.

The company's vision and mission is to make personalized medicine gigantic progresses available to researchers, clinicians and eventually patients, and positions itself as a leading provider of comprehensive nucleic acid information, empowering researchers and healthcare providers to unlock breakthroughs in cancer care as well as inherited & infectious diseases.

There are 42 IntegraGeners employed as of December 2023, and the Company generated €11.8 million of turnover in 2023. Located in France in Évry, IntegraGen leverages the assets & competencies of the Paris Genomic campus at the Génopole. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 – Mnemo: ALINT – Eligible PEA- PME).